GINA Difficult-to-treat & severe asthma in adolescent and adult patients. Diagnosis and management; 2021. Available from: https://ginasthma.org/wp-content/uploads/2021/08/SA-Pocket-guide-v3.0-SCREEN-WMS.pdf. [cited 2021 Nov 16]

Humbert M, Bousquet J, Bachert C, Palomares O, Pfister P, Kottakis I et al (2019) IgE-mediated multimorbidities in allergic asthma and the potential for omalizumab therapy. J Allergy Clin Immunol Pract 7:1418–1429

Article  Google Scholar 

Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J et al (2015) Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J 46:1308–1321

CAS  Article  Google Scholar 

Pretolani M, Soussan D, Poirier I, Thabut G, Aubier M, COBRA Study Group et al (2017) Clinical and biological characteristics of the French COBRA cohort of adult subjects with asthma. Eur Respir J 50:1700019. https://doi.org/10.1183/13993003.00019-2017

Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN et al (2020) Characterization of severe asthma worldwide: data from the international severe asthma registry. Chest 157:790–804

CAS  Article  Google Scholar 

Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S et al (2020) European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 58(Suppl S29):1–464

Bilodeau L, Boulay M-E, Prince P, Boisvert P, Boulet L-P (2010) Comparative clinical and airway inflammatory features of asthmatics with or without polyps. Rhinology 48:420–425

Article  Google Scholar 

Bhattacharyya N, Villeneuve S, Joish VN, Amand C, Mannent L, Amin N et al (2019) Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope 129:1969–1975

Article  Google Scholar 

Bagnasco D, Brussino L, Bonavia M, Calzolari E, Caminati M, Caruso C et al (2020) Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis. Respir Med 171:106080. https://doi.org/10.1016/j.rmed.2020.106080

Article  Google Scholar 

Blakey JD, Price DB, Pizzichini E, Popov TA, Dimitrov BD, Postma DS et al (2017) Identifying risk of future asthma attacks using UK medical record data: a respiratory effectiveness group initiative. J Allergy Clin Immunol Pract 5:1015–1024

Article  Google Scholar 

Mümmler C, Dünzelmann K, Kneidinger N, Barnikel M, Munker D, Gröger M et al (2021) Real-life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP. Clin Transl Allergy 11:e12049. https://doi.org/10.1002/clt2.12049

CAS  Article  Google Scholar 

Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394:1638–1650

CAS  Article  Google Scholar 

Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE et al (2020) Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 146:595–605

CAS  Article  Google Scholar 

Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE et al (2021) Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 9:1141–1153

CAS  Article  Google Scholar 

Heinzerling L, Mari A, Bergmann K-C, Bresciani M, Burbach G, Darsow U et al (2013) The skin prick test - European standards. Clin Transl Allergy 3:3. https://doi.org/10.1186/2045-7022-3-3

Article  Google Scholar 

Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A et al (2005) Standardisation of spirometry. Eur Respir J 26:319–338

CAS  Article  Google Scholar 

GINA Main Report 2021.Available from: https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf. [cited 2021 Nov 21]

Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W et al (2013) Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 131:110-116.e1

CAS  Article  Google Scholar 

Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K (2016) ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy 71:593–610

CAS  Article  Google Scholar 

Alhossan A, Lee CS, MacDonald K, Abraham I (2017) ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis. J Allergy Clin Immunol Pract 5:1362-1370.e2

Article  Google Scholar 

Damask C, Chen M, Holweg CTJ, Yoo B, Millette LA, Franzese C (2022) Defining the efficacy of omalizumab in nasal polyposis: a POLYP 1 and POLYP 2 subgroup analysis. Am J Rhinol Allergy 36:135–141

Article  Google Scholar 

Novartis. Xolair (omalizumab) label. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103976s5238lbl.pdf#page=36. [cited 2021 Dec 21]

Agache I, Song Y, Alonso-Coello P, Vogel Y, Rocha C, Solà I et al (2021) Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. Allergy 76:2337–2353

CAS  Article  Google Scholar 

Tsabouri S, Ntritsos G, Koskeridis F, Evangelou E, Olsson P, Kostikas K (2021) Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis. Rhinology 59:501–510

CAS  Google Scholar 

Bidder T, Sahota J, Rennie C, Lund VJ, Robinson DS, Kariyawasam HH (2018) Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study. Rhinology 56:42–45

CAS  Article  Google Scholar 

Heffler E, Saccheri F, Bartezaghi M, Canonica GW (2020) Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis. Clin Transl Allergy 10:25. https://doi.org/10.1186/s13601-020-00330-1

CAS  Article  Google Scholar 

Ruiz-Hornillos J, Rodríguez Jiménez B, Feliu Vila A, Moreno Fernández A, Hernández García MJ, Domínguez-Ortega J et al (2020) Omalizumab as a therapeutic option for nasal polyposis in moderate-to-severe persistent allergic asthma: evidence from a prospective study in a real-world setting. J Investig Allergol Clin Immunol 30:470–472

CAS  Article  Google Scholar 

Tiotiu A, Oster JP, Roux PR, Nguyen Thi PL, Peiffer G, Bonniaud P et al (2020) Effectiveness of omalizumab in severe allergic asthma and nasal polyposis: a real-life study. J Investig Allergol Clin Immunol 30:49–57

CAS  Article  Google Scholar 

GlaxoSmithKline LLC. Nucala (mepolizumab) label. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761122s006,125526s018lbl.pdf. [cited 2021 Dec 26]

Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A et al (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371:1198–1207

Article  Google Scholar 

Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J et al (2019) Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol 143:1742-1751.e7

CAS  Article  Google Scholar 

Howarth P, Chupp G, Nelsen LM, Bradford ES, Bratton DJ, Smith SG et al (2020) Severe eosinophilic asthma with nasal polyposis: a phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy. J Allergy Clin Immunol 145:1713–1715

CAS  Article  Google Scholar 

AstraZeneca. Fasenra (benralizumab) label. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761070s005lbl.pdf. [cited 2021 Dec 28]

Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG et al (2021) Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med 9:260–274

CAS  Article  Google Scholar 

Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C et al (2021) Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol S0091–6749(21):01459–01467. https://doi.org/10.1016/j.jaci.2021.08.030

CAS  Article  Google Scholar 

Canonica GW, Harrison TW, Chanez P, Menzella F, Louis R, Cosio BG et al (2022) Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. Allergy 77:150–161

CAS  Article  Google Scholar 

Lombardo N, Pelaia C, Ciriolo M, Della Corte M, Piazzetta G, Lobello N et al (2020) Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma. Int J Immunopathol Pharmacol 34:2058738420950851. https://doi.org/10.1177/2058738420950851

CAS  Article  Google Scholar 

Wenzel SE (2021) Severe adult asthmas: integrating clinical features, biology, and therapeutics to improve outcomes. Am J Respir Crit Care Med 203:809–821

CAS  Article  Google Scholar 

Taillé C, Chanez P, Devouassoux G, Didier A, Pison C, Garcia G et al (2020) Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. Eur Respir J 55:1902345. https://doi.org/10.1183/13993003.02345-2019

CAS  Article  Google Scholar 

Kavanagh JE, Hearn AP, Dhariwal J, d’Ancona G, Douiri A, Roxas C et al (2021) Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest 159:496–506

CAS  Article  Google Scholar 

Humbert M, Boulet LP, Niven RM, Panahloo Z, Blogg M, Ayre G (2009) Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. Allergy 64:81–84

CAS  Article  Google Scholar 

Samitas K, Carter A, Kariyawasam HH, Xanthou G (2018) Upper and lower airway remodelling mechanisms in asthma, allergic rhinitis and chronic rhinosinusitis: the one airway concept revisited. Allergy 73:993–1002

CAS  Article  Google Scholar 

Tiotiu A, Novakova P, Baiardini I, Bikov A, Chong-Neto H, de-Sousa JC et al (2021) Manifesto on united airways diseases (UAD): an Interasma (global asthma association - GAA) document. J Asthma 1–16. https://doi.org/10.1080/02770903.2021.1879130

Bandi F, Gallo S, Preti A, Mozzanica F, Visca D, Marelli M et al (2020) Effects of biological therapies on chronic rhinosinusitis in severe asthmatic patients. Acta Otorhinolaryngol Ital 40:435–443

Article  Google Scholar